A dash of FLASH.
Varian announced yesterday that it received an investigational device exemption from the FDA to proceed with a clinical trial of FLASH-RT using its ProBeam proton therapy unit. The initial trial, called FAST-01, will treat roughly 10 patients with bone metastases. Before you go throwing a stack of paper in the air yelling, “protons?!,” remember that this will be one of the first human trials of FLASH. Therefore, the primary aim is to evaluate the workflow, feasibility, and early patient tolerance of FLASH. Also consider that before FLASH can make a major impact beyond just single-beam, superficial treatment, we’ll need to figure out how to treat deep-seated tumors with complex fields. | Varian Medical Systems 2020